A leading precision oncology company, to bring innovative clinical trials to cancer patients throughout the country in the Target Panc Program. Perthera, with its Oncology Operating System™, will serve as the centralized “Molecular CRO” under the umbrella protocol.
Chicago, IL // For the first time, Perthera AI’s proven data mining, analytics, optimization and care management platform is now available as an analytics solution for cancer centers to utilize with their own patient data, at no cost. A research study by Cedars Sinai, PanCAN and Perthera’s GIPOCS program was one of the first to utilize data from Perthera’s Analytics solution and was presented at ASCO ‘22.
Molecular profiling in pancreatic adenocarcinoma (PDAC) has gained traction and we recently demonstrated that targeting actionable alterations can improve patient (pt) outcomes using the Perthera Platform’s real-world evidence database.
Denver, CO // The new partnership will give oncologists who use Perthera access to the world’s only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Perthera will serve as Theralink’s CRO to help bring in and enroll oncology practices in Theralink’s TRACE program, as well as provide treatment matching services to Theralink’s oncology partners.
Holliston, MA // The collaborative effort will deliver molecular profiling, personalized treatment recommendations, and clinical trial matching to patients with colorectal cancer.
New York, NY // GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.
This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.
Holliston, MA // Perthera and Lazarex are matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology to advance precision medicine for cancer patients.
Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.
Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.